ClinicalTrials.gg

Program

pegdarbepoetin beta

Also written as “BCD-131” and “BCD-131 (pegdarbepoetin beta)”.

Its studies are mostly in Anemia, led by Biocad.

Furthest: phase 3, since Aug 7, 20253 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocad31 open or runningphase 3since Aug 7, 2025Apr 3, 2016none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2016First study: phase 1 study in Reticulocyte CountFirst studyNCT02731469 · 45 enrolled
  2. Apr 26, 2018Phase 2 study in AnemiaNCT03519243 · 75 enrolled · Belarus, Russian Federation
  3. Aug 7, 2025Phase 3 study in AnemiaNCT07119372 · 228 enrolled · Russia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07119372Anemia · Russia3Active, not recruitingMay 12, 2026228
NCT03519243Anemia · Belarus, Russian Federation2CompletedDec 1, 201875
NCT02731469Reticulocyte Count1CompletedMar 201745

How it is read

Names in the registry

  • “BCD-131”, 2 entries
  • “BCD-131 (pegdarbepoetin beta)”, 1 entry

Codes read as this program: BCD131.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.